Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis

Phase 2

Completed

Brief Summary: To evaluate the safety and tolerability of FG-3019 in subjects with Idiopathic Pulmonary Fibrosis (IPF) and the efficacy of FG-3019 for attenuating fibrosis in these subjects.

Detailed Description: Major Changes: FGCL-3019-049 Protocol Amendment 3 offers long-term extension of treatment with FG-3019 to eligible Cohort 1-EX (approximately 14 subjects) and Cohort 2 (approximately 28 subjects) subjects who complete the Week 48-EX and Week 48 assessments described in Protocol Amendment 2, respectively. A subject is eligible for long-term extension of treatment if the investigator, after discussion with the Fibrogen Medical Monitor, believes that the subject would benefit from continued treatment with FG-3019.

Recruitment & Eligibility

Inclusion Criteria

Age 35 to 80 years, inclusive.
Clinical diagnosis of IPF by high resolution computed tomography (HRCT) scan (and in some cases by surgical lung biopsy) and reduced lung function (forced vital capacity).
History of IPF of 5 years duration or less.
Evidence of progression of IPF within the last 3-12 months for Cohort 1, or within the last 18 months for Cohort 2 before screening.
Women of childbearing potential, and men, must be willing to use a medically acceptable method of contraception during the trial and 3 months after the last dose of study drug.

Main

Exclusion Criteria

Women who are pregnant or nursing.
History of any other types of lung or heart disease and any other medical conditions that, in the opinion of the investigator, would preclude the subject's participation in the study.
Clinically important abnormal laboratory tests.
Upper or lower respiratory tract infection of any type within 4 weeks of the first screening visit.
Acute exacerbation of IPF within 3 months of the first screening visit.
Use of certain medications within 4 weeks of the first screening visit.
Receipt of an investigational drug within 6 weeks of the first screening visit.
History of cancer of any type in the 5 years preceding the first screening visit, excluding non-melanomatous skin cancer, localized bladder cancer, or in situ cervical cancer.
Trauma or surgical procedures requiring hospitalization within 4 weeks of the first screening visit.
Planned elective surgery during the study including 4 weeks following the final dose of study drug.
History of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies.
Inability to cooperate with study personnel or history of non-compliance to a medical regimen.
Previous treatment with FG-3019.

Arm && Interventions

Group	Intervention	Description
Cohort 1/1-EX	FG-3019	Subjects with moderate to severe idiopathic pulmonary fibrosis (IPF) who have evidence of disease progression
Cohort 2/2-EX	FG-3019	Subjects with mild to moderate idiopathic pulmonary fibrosis (IPF) who have evidence of disease progression

Primary Outcome Measures

Name	Time	Method
To determine the safety and tolerability of FG-3019 administered at doses of 15 mg/kg (Cohort 1 and Cohort 1-EX) and 30 mg/kg (Cohort 2 and Cohort 2-EX) every 3 wks for 45 weeks, and every 3 weeks thereafter for three additional treatment years.	Cohort 1: Up to 60 weeks, Cohort 1-EX (original subjects): up to 109 weeks, Cohort 1-EX (subjects who complete Week 48-EX and continue in the trial): up to 151 weeks, Cohort 2: up to 58 weeks, Cohort 2-EX: up to 202 weeks

Secondary Outcome Measures

Name	Time	Method
To evaluate the effect of FG-3019 on the extent of pulmonary fibrosis in subjects with IPF.	Cohort 1: Up to 60 weeks, Cohort 1-EX (original subjects): up to 109 weeks, Cohort 1-EX (subjects who complete Week 48-EX and continue in the trial): up to 151 weeks, Cohort 2: up to 58 weeks, Cohort 2-EX: up to 202 weeks
To evaluate the effect of FG-3019 on pulmonary function in subjects with IPF.	Cohort 1: Up to 60 weeks, Cohort 1-EX (original subjects): up to 109 weeks, Cohort 1-EX (subjects who complete Week 48-EX and continue in the trial): up to 151 weeks, Cohort 2: up to 58 weeks, Cohort 2-EX: up to 202 weeks
To evaluate the effect of FG-3019 on dyspnea in subjects with IPF.	Cohort 1: Up to 60 weeks, Cohort 1-EX (original subjects): up to 109 weeks, Cohort 1-EX (subjects who complete Week 48-EX and continue in the trial): up to 151 weeks, Cohort 2: up to 58 weeks, Cohort 2-EX: up to 202 weeks

Locations (18): University of Alabama at Birmingham Hospital
🇺🇸
Birmingham, Alabama, United States
Tampa General Hospital
🇺🇸
Tampa, Florida, United States
The Ohio State University
🇺🇸
Columbus, Ohio, United States
St. Luke's Hospital
🇺🇸
Chesterfield, Missouri, United States
Vermont Lung Center
🇺🇸
Colchester, Vermont, United States
University of Louisville
🇺🇸
Louisville, Kentucky, United States
Rutgers-Robert Wood Johnson Medical School
🇺🇸
New Brunswick, New Jersey, United States
Mount Sinai
🇺🇸
New York, New York, United States
University of Texas Southwestern Medical Center
🇺🇸
Dallas, Texas, United States
Inova Fairfax Hospital
🇺🇸
Falls Church, Virginia, United States
Arizona Pulmonary Specialists, LTD
🇺🇸
Scottsdale, Arizona, United States
Emory University
🇺🇸
Atlanta, Georgia, United States
Yale University
🇺🇸
New Haven, Connecticut, United States
Central Florida Pulmonary Group, PA
🇺🇸
Orlando, Florida, United States
Vanderbilt University
🇺🇸
Nashville, Tennessee, United States
University of Utah - Lung Health Research
🇺🇸
Salt Lake City, Utah, United States
Via Christi Hospitals Wichita, Inc.
🇺🇸
Wichita, Kansas, United States
University of Wisconsin School of Medicine & Public Health
🇺🇸
Madison, Wisconsin, United States